Lymphoma immunophenotyping: A new era in paraffin-section immunohistochemistry

Advances in Anatomic Pathology

Volumn 8, Issue 4, 2001, Pages 218-239

  Hsi, Eric D ^a   Yegappan, Subramanian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Heat induced epitope retrieval; Hodgkin lymphoma; Immunohistochemistry; Lymphoma; Monoclonal antibody; Non Hodgkin lymphoma

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; ONCOPROTEIN; TUMOR MARKER;

HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOMA; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD; HUMANS; IMMUNOGLOBULINS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035403106     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/00125480-200107000-00003     Document Type: Review

References (304)

1. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92. (Pubitemid 24273002)
3. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13:193-207. (Pubitemid 30109108)
4. de Leon ED, Alkan S, Huang JC, et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol 1998;11:1046-51. (Pubitemid 28525009)
5. Calvo J, Padilla O, Places L, et al. Relevance of individual CD5 extracellular domains on antibody recognition, glycosylation and co-mitogenic signalling. Tissue Antigens 1999;54:16-26. (Pubitemid 29326926)
6. Simarro M, Calvo J, Vila JM, et al. Signaling through CD5 involves acidic sphingomyelinase, protein kinase C-zeta, mitogen-activated protein kinase, and c-Jun NH2-terminal kinase. J Immunol 1999;162:5149-55. (Pubitemid 29307117)
7. Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today 1999;20:312-6. (Pubitemid 29331536)
8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
9. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-78. (Pubitemid 27132123)
10. Pittaluga S, Wlodarska I, Stul MS, et al. Mantle cell lymphoma: a clinicopathologic study of 55 cases. Histopathology 1995;26:17-24.
11. Sundeen JT, Longo DL, Jaffe ES. CD5 expression in B-cell small lymphocytic malignancies. Correlations with clinical presentation and sites of disease. Am J Surg Pathol 1992;16:130-7.
12. Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol 1997;10:859-63. (Pubitemid 27431958)
13. Kaufmann O, Flath B, Spath-Schwalbe E, et al. Immunohistochemical detection of CD5 with monoclonal antibody 4C7 on paraffin sections. Am J Clin Pathol 1997;108:669-73. (Pubitemid 27506234)
14. Butmarc JR, Kourea HP, Levi E, et al. Improved detection of CD5 epitope in formalin-fixed paraffin-embedded sections of benign and neoplastic lymphoid tissues by using biotinylated tyramine enhancement after antigen retrieval. Am J Clin Pathol 1998;109:682-8. (Pubitemid 28247266)
15. Taniguchi M, Oka K, Hiasa A, et al. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998;91:1145-51. (Pubitemid 28086866)
16. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia 1999;13:1441-7.
17. Arber DA, Weiss LM. CD10: a review. Appl Immunohistochem 1997;5:125-40.
18. Shipp MA, Stefano GB, Switzer SN, et al. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide- induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood 1991;78:1834-41.
19. McIntosh GG, Lodge AJ, Watson P, et al. NCL-CD10-270: a new monoclonal antibody recognizing CD10 in paraffin-embedded tissue. Am J Pathol 1999;154:77-82. (Pubitemid 29031614)
20. Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. Follicular and diffuse lymphomas of small- cleaved-cell type are related but distinct entities. Am J Pathol 1984;117:262-72. (Pubitemid 15209040)
21. Hollema H, Poppema S. Immunophenotypes of malignant lymphoma centroblastic-centrocytic and malignant lymphoma centrocytic: an immunohistologic study indicating a derivation from different stages of B cell differentiation. Hum Pathol 1988;19:1053-9.
22. Kurtin PJ, Hobday KS, Ziesmer S, et al. Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol 1999;112:319-9.
23. Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 1998;83:967-73.
24. Uckun FM, Sather H, Gaynon P, et al. Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group. Leuk Lymphoma 1997;27:445-57. (Pubitemid 28029906)
25. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995;9:762-9.
26. Pui CH, Rivera GK, Hancock ML, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. Leukemia 1993;7:35-40. (Pubitemid 23048918)
27. Garcia CF, Weiss LM, Warnke RA. Small noncleaved cell lymphoma: an immunophenotypic study of 18 cases and comparison with large cell lymphoma. Hum Pathol 1986;17:454-61. (Pubitemid 16061451)
28. Fang JM, Finn WG, Hussong JW, et al. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma. Mod Pathol 1999;12:295-300. (Pubitemid 29133851)
29. Leveille C, Al Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. European J Immunol 1999;29:65-74. (Pubitemid 29043523)
30. Popoff IJ, Savage JA, Blake J, et al. The association between CD20 and Src-family Tyrosine kinases requires an additional factor. Mol Immunol 1998;35:207-14. (Pubitemid 28374928)
31. Chadburn A, Knowles DM. Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas. Am J Clin Pathol 1994;102:284-91. (Pubitemid 24330986)
32. Segal GH, Stoler MH, Fishleder AJ, et al. Reliable and cost-effective paraffin section immunohistology of lymphoproliferative disorders. Am J Surg Pathol 1991;15:1034-41.
33. Mason DY, Comans-Bitter WM, Cordell JL, et al. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990;136:1215-22. (Pubitemid 20210319)
34. Davey FR, Gatter KC, Ralfkiaer E, et al. Immunophenotyping of non-Hodgkin's lymphomas using a panel of antibodies on paraffin-embedded tissues. Am J Pathol 1987;129:54-63. (Pubitemid 17157770)
35. Takami A, Saito M, Nakao S, et al. CD20-positive T-cell chronic lymphocytic leukaemia. Br J Haematol 1998;102:1327-9. (Pubitemid 28435220)
36. Algino KM, Thomason RW, King DE, et al. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol 1996;106:78-81. (Pubitemid 26239325)
37. Quintanilla-Martinez L, Preffer F, Rubin D, et al. CD20+ T-cell lymphoma. Neoplastic transformation of a normal T-cell subset. Am J Clin Pathol 1994;102:483-9. (Pubitemid 24323344)
38. Vasef MA, Alsabeh R, Medeiros LJ, et al. Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease: a paraffin-section immunohistochemical study using the heat-induced epitope retrieval method. Am J Clin Pathol 1997;108:54-9. (Pubitemid 27276513)
39. Schmid C, Pan L, Diss T, et al. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol 1991;139:701-7.
40. Zukerberg LR, Collins AB, Ferry JA, et al. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. Am J Pathol 1991;139:475-83.
41. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000;95:1443-50. (Pubitemid 30099859)
42. Lin BT, Weiss LM. Primary plasmacytoma of lymph nodes. Hum Pathol 1997;28:1083-90. (Pubitemid 27388111)
43. Arber DA, Jenkins KA. Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. Am J Clin Pathol 1996;106:462-8. (Pubitemid 26332995)
44. Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999;111:467-76. (Pubitemid 29153142)
45. Strickler JG, Audeh MW, Copenhaver CM, et al. Immunophenotypic differences between plasmacytoma/multiple myeloma and immunoblastic lymphoma. Cancer 1988;61:1782-6.
46. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7. (Pubitemid 29269257)
47. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26:66-73. (Pubitemid 29523413)
48. Mclaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999;26:79-87. (Pubitemid 29523415)
49. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-61. (Pubitemid 29342370)
50. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, et al. Structure and functions of CD23. Int Rev Immunol 1997;16:113-28. (Pubitemid 28073173)
51. Zukerberg LR, Medeiros LJ, Ferry JA, et al. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol 1993;100:373-85. (Pubitemid 23296501)
52. Watson P, Wood KM, Lodge A, et al. Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphoma. Histopathology 2000;36:145-50. (Pubitemid 30113976)
53. Kumar S, Green GA, Teruyafeldstein J, et al. Cd23, mantle cell lymphoma, Paraffin section immunostaining, small, lymphocytic lymphoma: use of CD23 (BU38) on paraffin in sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod Pathol 1996;9:925-9. (Pubitemid 26319723)
54. Lampert IA, Wotherspoon A, Van Noorden S, et al. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum Pathol 1999;30:648-54. (Pubitemid 29266723)
55. Asplund SL, Hsi ED, Shapiro JL, et al. Discordant CD23 expression in mantle cell lymphoma. Am J Clin Pathol 1998;110:534.
56. Arber D A, Weiss LM. CD43; a review. Appl Immunohistochem 1993;1:88-96.
57. Stross WP, Warnke RA, Flavell DJ, et al. Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen. J Clin Pathol 1989;42:953-61. (Pubitemid 19225457)
58. Said JW, Stoll PN, Shintaku P, et al. Leu-22: a preferential marker for T-lymphocytes in paraffin sections. Staining profile in T- and B-cell lymphomas, Hodgkin's disease, other lymphoproliferative disorders, myeloproliferative diseases, and various neoplastic processes. Am J Clin Pathol 1989;91:542-9. (Pubitemid 19130279)
59. Norton AJ, Isaacson PG. Lymphoma phenotyping in formalin-fixed and paraffin wax-embedded tissues. I. Range of antibodies and staining patterns. Histopathology 1989;14:437-46. (Pubitemid 19137146)
60. Ngan BY, Picker LJ, Medeiros LJ, et al. Immunophenotypic diagnosis of non-Hodgkin's lymphoma in paraffin sections. Coexpression of L60 (Leu-22) and L26 antigens correlates with malignant histologic findings. Am J Clin Pathol 1989;91:579-83. (Pubitemid 19130285)
61. Picker LJ, Weiss LM, Medeiros LJ, et al. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol 1987;128:181-201. (Pubitemid 17094347)
62. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol 1999;111:488-94. (Pubitemid 29153144)
63. Hsi ED, Zukerberg LR, Schnitzer B, et al. Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Mod Pathol 1995;8:817-24.
64. Segal GH, Stoler MH, Tubbs RR. The 'CD43 only' phenotype. An aberrant, nonspecific immunophenotype requiring comprehensive analysis for lineage resolution. Am J Clin Pathol 1992;97:861-5.
65. Lai R, Visser L, Poppema S. Tissue distribution of restricted leukocyte common antigens. A comprehensive study with protein- and carbohydrate-specific CD45R antibodies. Lab Invest 1991;64:844-54.
66. Streuli M, Morimoto C, Schrieber M, et al. Characterization of CD45 and CD45R monoclonal antibodies using transfected mouse cell lines that express individual human leukocyte common antigens. J Immunol 1988;141:3910-4.
67. Poppema S, Hollema H, Visser L, et al. Monoclonal antibodies (MT1, MT2, MB1, MB2, MB3) reactive with leukocyte subsets in paraffin-embedded tissue sections. Am J Pathol 1987;127:418-29. (Pubitemid 17089803)
68. Chilosi M, Mombello A, Menestrina F, et al. Immunohistochemical differentiation of follicular lymphoma from florid reactive follicular hyperplasia with monoclonal antibodies reactive on paraffin sections. Cancer 1990;65:1562-9. (Pubitemid 20106116)
69. Utz GL, Swerdlow SH. Distinction of follicular hyperplasia from follicular lymphoma in B5-fixed tissues: comparison of MT2 and bcl-2 antibodies. Hum Pathol 1993;24:1155-8. (Pubitemid 23352323)
70. Norton AJ, Isaacson PG. Detailed phenotypic analysis of B-cell lymphoma using a panel of antibodies reactive in routinely fixed wax-embedded tissue. Am J Pathol 1987;128:225-40. (Pubitemid 17127151)
71. Fend F, Kraus-Huonder B, Muller-Hermelink HK, et al. Monocytoid B-cell lymphoma: its relationship to and possible cellular origin from marginal zone cells. Hum Pathol 1993;24:336-9. (Pubitemid 23086371)
72. Pawade J, Wilkins BS, Wright DH. Low-grade B-cell lymphomas of the splenic marginal zone: a clinicopathological and immunohistochemical study of 14 cases. Histopathology 1995;27:129-37.
73. Kawano S, Tatsumi E, Yoneda N, et al. Expression pattern of CD45 RA/RO isoformic antigens in T-lineage neoplasms. Am J Hematol 1995;49:6-14.
74. Ng CS, Chan JK, Hui PK, et al. Monoclonal antibodies reactive with normal and neoplastic T cells in paraffin sections. Hum Pathol 1988;19:295-303.
75. van Noesel CJ, van Lier RA, Cordell JL, et al. The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene. J Immunol 1991;146:3881-8.
76. Borst J, Brouns GS, de Vries E, et al. Antigen receptors on T and B lymphocytes: parallels in organization and function. Immunol Rev 1993; 132:49-84. (Pubitemid 23151214)
77. Mason DY, Cordell JL, Brown MH, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995;86:1453-9.
78. Chuang SS, Li CY. Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. Am J Clin Pathol 1997;107:410-8.
79. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783-6.
80. Arber DA, Jenkins KA, Slovak ML. CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Am J Pathol 1996;149:1105-10. (Pubitemid 26337229)
81. Bhargava P, Kallakury BVS, Ross JS, et al. CD79a is heterogenously expressed in acute nonal-lymphoblastic leukemias (ANLL) and normal megakaryocytes and is antibody clone dependent. Mod Pathol 2000;13:143a.
82. Pilozzi E, Pulford K, Jones M, et al. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma. J Pathol 1998;186:140-3. (Pubitemid 28467822)
83. Pezzella F, Ralfkiaer E, Gatter KC, et al. The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 1990;76:58-64. (Pubitemid 20326795)
84. Weiss LM, Warnke RA, Sklar J, et al. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Eng J Med 1987;317:1185-9. (Pubitemid 17150330)
85. Horsman DE, Gascoyne RD, Coupland RW, et al. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 1995;103:472-8.
86. Lai R, Arber DA, Chang KL, et al. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol 1998;11:864-9. (Pubitemid 28440883)
87. Volkenandt M, Cerroni L, Rieger E, et al. Analysis of the 14;18 translocation in cutaneous lymphomas using the polymerase chain reaction. J Cutaneous Pathology 1992;19:353-6.
88. Yang B, Tubbs RR, Finn W, et al. Clinicopathologic reassessment of primary cutaneous B-cell lymphomas with immunophenotypic and molecular genetic characterization. Am J Surg Pathol 2000;24:694-702. (Pubitemid 30253507)
89. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996;14:2131-8. (Pubitemid 26230116)
90. Albagli O, Lantoine D, Quief S, et al. Overexpressed BCL6 (LAZ3) oncoprotein triggers apoptosis, delays S phase progression and associates with replication foci. Oncogene 1999;18:5063-75. (Pubitemid 29443752)
91. Baron BW, Stanger RR, Hume E, et al. BCL6 encodes a sequence-specific DNA-binding protein. Genes Chromosomes Cancer 1995;13:221-4.
92. Kerckaert JP, Deweindt C, Tilly H, et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 1993;5:66-70. (Pubitemid 23261521)
93. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2- type inflammation. Nat Genet 1997;16:161-70.
94. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998;92:3152-62. (Pubitemid 28492322)
95. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol 1997;183:281-6. (Pubitemid 27505212)
96. Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994;83:2423-7. (Pubitemid 24135832)
97. Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci U S A 1998;95:11816-21. (Pubitemid 28460497)
98. Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998;280:1750-2. (Pubitemid 28283498)
99. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and guide clinical outcome. Blood 1998;92:2294-2302. (Pubitemid 28452970)
100. Gaidano G, Carbone A, Pastore C, et al. Frequent mutation of the 5′ noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1997;89:3755-62. (Pubitemid 27227099)
101. Liang R, Chan WP, Kwong YL, et al. Bcl-6 gene hypermutations in diffuse large B-cell lymphoma of primary gastric origin. Br J Haematol 1997;99:668-70. (Pubitemid 27519872)
102. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53.
103. Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol 1996;148:1543-55.
104. Carbone A, Gaidano G, Gloghini A, et al. BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression. Am J Pathol 1997;150:155-65. (Pubitemid 27027106)
105. Raible MD, Hsi ED, Diaz de Leon E, et al. bcl-6 protein expression in follicle center cell lymphomas: a marker for distinguishing these lymphomas from other low grade-lymphoproliferative disorders. Am J Clin Pathol 1999;112:101-7. (Pubitemid 30214741)
106. Skinnider BF, Horsman DE, Dupuis B, et al. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999;30:803-8. (Pubitemid 29325787)
107. Carbone A, Gloghini A, Gaidano G, et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 1998;92:2220-8. (Pubitemid 28452961)
108. Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996;87:465-71. (Pubitemid 26030301)
109. Carbone A, Gloghini A, Gaidano G, et al. BCL-6 protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood 1997;90:2445-50. (Pubitemid 27392729)
110. Offit K, Lo Coco F, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331:74-80.
111. Motokura T, Bloom T, Kim HG, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5. (Pubitemid 21912266)
112. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Nat Acad Sci USA 1991;88:9638-42. (Pubitemid 21915686)
113. Williams ME, Swerdlow SH, Rosenberg CL, et al. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992;52:5541s-4s.
114. Williams ME, Swerdlow SH, Rosenberg CL, et al. Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia 1993;7:241-5. (Pubitemid 23079234)
115. Williams ME, Swerdlow SH. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann Oncol 1994[5 Suppl];1:71-3. (Pubitemid 24051321)
116. Luthra R, Hai S, Pugh WC. Polymerase chain reaction detection of the t(11;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol 1995;4:4-7.
117. Ott MM, Helbing A, Ott G, et al. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol 1996;179:238-42. (Pubitemid 26266399)
118. Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994;83:1871-5. (Pubitemid 24107911)
119. Segal GH, Maiese RL. Mantle cell lymphoma - rapid polymerese chain raction-based genotyping of a morphologically heterogeneous entity. Arch Pathol Lab Med 1996;120:835-41. (Pubitemid 26326105)
120. Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999;154:1449-52. (Pubitemid 29226440)
121. Monteil M, Callanan M, Dascalescu C, et al. Cytogenetics, T(11-14)(q13-q32), fish, interphase nuclei: molecular diagnosis of T(11-14) in mantle cell lymphoma using two-color interphase flourescence in situ hybridization. Br J Haematol 1996;93:656-60. (Pubitemid 26168610)
122. Swerdlow SH, Yang WI, Zukerberg LR, et al. Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCL1/cyclin D1 gene. Human Pathology 1995;26:999-1004.
123. Singh N, Wright DH. The value of immunohistochemistry on paraffin wax embedded tissue sections in the differentiation of small lymphocytic and mantle cell lymphomas. J Clin Pathol 1997;50:16-21. (Pubitemid 27060198)
124. Kuroda H, Komatsu H, Nakamura S, et al. The positive nuclear staining observed with monoclonal antibody against PRAD1/cyclin D1 correlates with mRNA expression in mantle cell lymphoma. Japanese J Cancer Res 1995;86:890-8.
125. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 1995;86:2715-23.
126. Zukerberg LR, Yang WI, Arnold A, et al. Cyclin D1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. A J Clin Pathol 1995;103:756-60.
127. Yang WI, Zukerberg LR, Motokura T, et al. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86-96. (Pubitemid 24217487)
128. Vasef MA, Medeiros LJ, Koo C, et al. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol 1997;108:302-7. (Pubitemid 27371649)
129. Chan JK, Miller KD, Munson P, et al. Immunostaining for cyclin D1 and the diagnosis of mantle cell lymphoma: is there a reliable method? Histopathology 1999;34:266-70. (Pubitemid 29152017)
130. Brynes RK, McCourty A, Tamayo R, et al. Epitope retrieval, Ultrasound, Cyclin D1, Bcl-1.: Demonstration of cyclin D1 (BCL-L) in mantle cell lymphoma - enhanced staining using heat and ultrasound epitope retrieval. Appl Immunohistochem 1997;5:45-8.
131. Aguilera NS, Uusafr M, Wenig BM, et al. The blastic variant of mantle cell lymphoma arising in Waldeyer's tonsillar ring. J Laryngol Otol 1998;112:991-4. (Pubitemid 28468456)
132. Bosch F, Campo E, Jares P, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol 1995;91:1025-30.
133. de Boer CJ, Kluin-Nelemans JC, Dreef E, et al. Involvement of the CCND1 gene in hairy cell leukemia. Ann Oncology 1996;7:251-6. (Pubitemid 26130589)
134. Vasef MA, Medeiros LJ, Yospur LS, et al. Cyclin D1 protein in multiple myeloma and plasmacytoma: an immunohistochemical study using fixed, paraffin-embedded tissue sections. Mod Pathol 1997;10:927-32. (Pubitemid 27431968)
135. Merz H, Rickers O, Schrimel S, et al. Constant detection of surface and cytoplasmic immunoglobulin heavy and light chain expression in formalin-fixed and paraffin-embedded material. J Pathol 1993;170:257-64. (Pubitemid 23234872)
136. Ashton-Key M, Jessup E, Isaacson PG. Immunoglobulin light chain staining in paraffin-embedded tissue using a heat mediated epitope retrieval method. Histopathology 1996;29:525-31. (Pubitemid 26422826)
137. Kelenyi G. Intracellular J chains in lymphoproliferative diseases. Virchows Arch A Pathol Anat Histopathol 1985;405:365-78. (Pubitemid 15171681)
138. Schmid C, Sargent C, Isaacson PG. L and H cells of nodular lymphocyte predominant Hodgkin's disease show immunoglobulin light-chain restriction. Am J Pathol 1991;139:1281-9.
139. Campo, E, Miquel, R, Krenacs, L, et al. Primary nodal marginal zone lymphomas or splenic and MALT type. Am J Surg Pathol 1999;23:59-68. (Pubitemid 29025241)
140. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
141. Lee SS, Cho KJ, Kim CW, et al. Clinicopathologic analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms. Histopathology 1999;35:345-54. (Pubitemid 29502353)
142. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 1993;72:1762-72. (Pubitemid 23249308)
143. Kuppers R, Klein U, Hansmann ML, et al. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-9. (Pubitemid 29526356)
144. Cabecadas JM, Isaacson PG. Phenotyping of T-cell lymphomas in paraffin sections-which antibodies? Histopathology 1991;19:419-24.
145. Winberg CD. Peripheral T-cell lymphoma. Morphologic and immunologic observations. Am J Clin Pathol 1993;99:426-35. (Pubitemid 23126843)
146. Moll M, Reinhold U, Kukel Set al. CD7-negative helper T cells accumulate in inflammatory skin lesions. J Invest Dermatol 1994;102:328-32. (Pubitemid 24095499)
147. Krenacs L, Tiszalvicz L, Krenacs T, et al. Immunohistochemical detection of CD1A antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010. J Pathol 1993;171:99-104. (Pubitemid 23309730)
148. Emile JF, Wechsler J, Brousse N, et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol 1995;19:636-41.
149. Hastrup N, Ralfkiaer E, Pallesen G. Aberrant phenotypes in peripheral T cell lymphomas. J Clin Pathol 1989;42:398-402. (Pubitemid 19121587)
150. Pileri SA, Ascani S, Milani M, et al. Acute leukaemia immunophenotyping in bone-marrow routine sections. Br J Haematol 1999;105:394-401. (Pubitemid 29232160)
151. Steward M, Bishop R, Piggott NH, et al. Production and characterization of a new monoclonal antibody effective in recognizing the CD3 T-cell associated antigen in formalin-fixed embedded tissue. Histopathology 1997;30:16-22. (Pubitemid 27072444)
152. Chadburn A, Husain S, Knowles DM. Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections. Hum Pathol 1992;23:940-7.
153. Facchetti F, Chan JK, Zhang W, et al. Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathologic conditions. Am J Pathol 1999;154:1037-46. (Pubitemid 29169738)
154. Toth B, Wehrmann M, Kaiserling E, et al. Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. J Clin Pathol 1999;52:688-92. (Pubitemid 29456907)
155. Chuang SS, Li CY. Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. Am J Clin Pathol 1997;107:410-8.
156. Kurtin PJ, Roche PC. Immunoperoxidase staining of non-Hodgkin's lymphomas for T-cell lineage associated antigens in paraffin sections. Comparison of the performance characteristics of four commercially available antibody preparations. Am J Surg Pathol 1993;17:898-904. (Pubitemid 23245922)
157. Jaffe ES, Chan JK, Su IJ, et al.: Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. American J Surg Pathol 1996;20:103-11.
158. Lanier LL, Chang C, Spits H, et al. Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes. J Immunol 1992;149:1876-80.
159. Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000;95:3020-4. (Pubitemid 30321149)
160. Enblad G, Sundstrom C, Glimelius B. Immunohistochemical characteristics of Hodgkin and Reed-Sternberg cells in relation to age and clinical outcome. Histopathology 1993;22:535-41. (Pubitemid 23197954)
161. Kurtin PJ, Roche PC. Immunoperoxidase staining of non-Hodgkin's lymphomas for T-cell lineage associated antigens in paraffin sections. Comparison of the performance characteristics of four commercially available antibody preparations. Am J Surg Pathol 1993;17:898-904. (Pubitemid 23245922)
162. von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997;150:793-803. (Pubitemid 27106151)
163. Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity? Histopathology 2000;36:294-305. (Pubitemid 30198911)
164. Boulland ML, Wechsler J, Bagot M, et al. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000;36:136-44. (Pubitemid 30113975)
165. Kummer JA, Vermeer MH, Dukers D, et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997;109:636-40. (Pubitemid 27465917)
166. Macon WR, Salhany KE. T-cell subset analysis of peripheral T-cell lymphomas by paraffin section immunohistology and correlation of CD4/CD8 results with flow cytometry. Am J Clin Pathol 1998;109:610-7. (Pubitemid 28191551)
167. Williamson SL, Steward M, Milton I, et al. New monoclonal antibodies to the T cell antigens CD4 and CD8. Production and characterization in formalin-fixed paraffin-embedded tissue. Am J Pathol 1998;152:1421-6. (Pubitemid 28275000)
168. Yagita M, Huang CL, Umehara H, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 2000;14:922-30. (Pubitemid 30235072)
169. Wood GS, Abel EA, Hoppe RT, et al. Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation. J Am Acad Dermatol 1986;14:1006-13. (Pubitemid 16090436)
170. Ormsby AH, Tubbs RR, Bergfeld WF, et al. A new CD7 paraffin reactive antibody and T-γ PCR monoclonality are sensitive and specific for a diagnosis of MF. Mod Pathol 2000;13:66a.
171. Chott A, Augustin I, Wrba F, et al. Peripheral T-cell lymphomas: a clinicopathologic study of 75 cases. Hum Pathol 1990;21:1117-25. (Pubitemid 20381994)
172. Norton AJ, Ramsay AD, Smith SH, et al. Monoclonal antibody (UCHL1) that recognises normal and neoplastic T cells in routinely fixed tissues. J Clin Pathol 1986;39:399-405. (Pubitemid 16046770)
173. Clark JR, Williams ME, Swerdlow SH. Detection of B- and T-cells in paraffin-embedded tissue sections. Diagnostic utility of commercially obtained 4KB5 and UCHL-1. Am J Clin Pathol 1990;93:58-69. (Pubitemid 20038939)
174. Falini B, Pileri S, Stein H, et al. Variable expression of leucocyte-common (CD45) antigen in CD30 (Ki1)-positive anaplastic large-cell lymphoma: implications for the differential diagnosis between lymphoid and nonlymphoid malignancies. Hum Pathol 1990;21:624-9. (Pubitemid 20204951)
175. Gloghini A, De Paoli P, Gaidano G, et al. High frequency of CD45RO expression in AIDS-related B-cell non-Hodgkin's lymphomas. Am J Clin Pathol 1995;104:680-8. (Pubitemid 26001446)
176. Menasce LP, Banerjee SS, Beckett E, et al. Extra-medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology 1999;34:391-8. (Pubitemid 29244162)
177. Shipley WR, Hammer RD, Lennington WJ, et al. Paraffin Immunohistochemical Detection of CD56, a Useful Marker for Neural Cell Adhesion Molecule (NCAM), in Normal and Neoplastic Fixed Tissues. Appl Immunohistochem 1997;5:87-93.
178. Tsang WY, Chan JK, Ng CS, et al. Utility of a paraffin section-reactive CD56 antibody (123C3) for characterization and diagnosis of lymphomas. Am J Surg Pathol 1996;20:202-10. (Pubitemid 26038997)
179. Chan JK. Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Mod Pathol 1999;12:177-99. (Pubitemid 29093901)
180. Chott A, Haedicke W, Mosberger I, et al. Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 1998;153:1483-90. (Pubitemid 28509905)
181. Ohshima K, Haraoka S, Harada N, et al. Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology 2000;36:127-35. (Pubitemid 30113974)
182. Wong KF, Chan JK, Matutes E, et al. Hepatosplenic gamma delta T-cell lymphoma. A distinctive aggressive lymphoma type. Am J Surg Pathol 1995;19:718-26.
183. Cooke CB, Krenacs L, Stetler-Stevenson M, et al. Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996;88:4265-74. (Pubitemid 26399174)
184. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998;22:881-93. (Pubitemid 28328234)
185. Yamashita Y, Yatabe Y, Tsuzuki T, et al. Perforin and granzyme expression in cytotoxic T-cell lymphomas. Mod Pathol 1998;11:313-23. (Pubitemid 28208091)
186. Felgar RE, Salhany KE, Macon WR, et al. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol 1999;30:228-36. (Pubitemid 29086957)
187. Hammer RD, Vnencak-Jones CL, Manning SS, et al. Microvillous lymphomas are B-cell neoplasms that frequently express CD56. Mod Pathol 1998;11:239-46. (Pubitemid 28131532)
188. Arber DA, Weiss LM. CD57: a Review. Appl Immunohistochem 1995;3:137-52.
189. Kamel OW, Gelb AB, Shibuya RB, et al. Leu 7 (CD57) reactivity distinguishes nodular lymphocyte predominance Hodgkin's disease from nodular sclerosing Hodgkin's disease, T-cell-rich Bcell lymphoma and follicular lymphoma. Am J Pathol 1993;142:541-6. (Pubitemid 23057467)
190. von Wasielewski R, Werner M, Fischer R, et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997;150:793-803. (Pubitemid 27106151)
191. Nguyen PL, Ferry JA, Harris NL. Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study. Am J Surg Pathol 1999;23:27-33. (Pubitemid 29025238)
192. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91:2076-84. (Pubitemid 28185511)
193. Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994;84:3648-52.
194. Hutchison RE, Banki K, Shuster JJ, et al. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 1997[8 Suppl];1:37-42.
195. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997;89:1394-1404. (Pubitemid 27080004)
196. Falini B, Bigerna B, Fizzotti M, et al. ALK expression defines a distinct group of T/null lymphomas with a wide morphological spectrum. Am J Pathol 1998;153:875-6.
197. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 2000;156:1711-21. (Pubitemid 30646709)
198. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:341-5.
199. Lamant L, Meggetto F, AL Saati T, et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996;87:284-91.
200. Nakamura S, Shiota M, Nakagawa A, et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 1997;21:1420-32. (Pubitemid 27528252)
201. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-90. (Pubitemid 27097438)
202. Su LD, Schnitzer B, Ross CW, et al. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 1997;24:597-603. (Pubitemid 27515696)
203. DeCoteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996;87:3437-41.
204. Colleoni GW, Bridge JA, Garicochea B, et al. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000;156:781-9. (Pubitemid 30626935)
205. Wlodarska I, Wolf-Peeters C, Falini B, et al. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma. Blood 1998;92:2688-95. (Pubitemid 28469080)
206. Lamant L, Dastugue N, Pulford K, et al. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088-95. (Pubitemid 29200802)
207. Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 1999;94:3265-8. (Pubitemid 29512738)
208. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204-7. (Pubitemid 30321174)
209. Tort F, Pinyol M, Pulford K, et al. Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma. Lab Invest 2001;81:419-26. (Pubitemid 32245073)
210. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999;94:3509-15. (Pubitemid 29536146)
211. Cordell JL, Pulford KAF, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999;93:632-42. (Pubitemid 29035746)
212. Said JW, Shintaku IP, Parekh K, et al. Specific phenotyping of T-cell proliferations in formalin-fixed paraffin-embedded tissues. Use of antibodies to the T-cell receptor beta F1. Am J Clin Pathol 1990;93:382-6. (Pubitemid 20103065)
213. Krajewski AS, Myskow MW, Salter DM, et al. Diagnosis of T-cell lymphoma using beta F1, antiT-cell receptor beta chain antibody. Histopathology 1989;15:239-47. (Pubitemid 19232647)
214. Gaulard P, Bourquelot P, Kanavaros P, et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 1990;137:617-28. (Pubitemid 20280991)
215. Macon WR, Levy NB, Casey TT, et al. Hepatosplenic αβ T-cell lymphomas: a report of four cases with features similar to hepatosplenic γδ T-cell lymphomas. Mod Pathol 1998;11:135.
216. Arnulf B, Copie-Bergman C, Delfau-Larue MH, et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998;91:1723-31. (Pubitemid 28110338)
217. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med 1991;325:1078-81.
218. Delsol G, Blancher A, Saati T, et al. Antibody BNH9 detects red blood cell-related antigens on anaplastic large cell (CD30+) lymphomas. Br J Cancer 1991;64:321-6.
219. Carbone A, Gloghini A, Volpe R. Immunohistochemistry of Hodgkin and nonHodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas. Cancer 1992;70:2691-8.
220. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-13. (Pubitemid 29512717)
221. Stein H. Hodgkin's disease. Proposal for the World Health Organization (WHO) classification of Hodgkin's disease (Hodgkin's lymphoma). Am J Surg Pathol 1997;21:119-20.
222. Tamaru J, Hummel M, Zemlin M, et al. Hodgkin's disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 1994;84:708-15.
223. Chittal SM, Al Saati T, Delsol G. Epithelial membrane antigen in hematolymphoid neoplasms: a review. Appl Immunohistochem 1997;203-15.
224. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998;91:2076-84. (Pubitemid 28185511)
225. Delsol G, Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988;130:59-70. (Pubitemid 18044833)
226. Delsol G, Gatter KC, Stein H, et al. Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet 1984;2:1124-9. (Pubitemid 15210848)
227. Felgar RE, Macon WR, Kinney MC, et al. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997;150:1893-1900. (Pubitemid 27233062)
228. Kumar S, Krenacs L, Medeiros J, et al. Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998;29:397-403. (Pubitemid 28231906)
229. Krenacs L, Wellmann A, Sorbara L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 1997;89:980-9. (Pubitemid 27121292)
230. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996;88:4005-11. (Pubitemid 26383125)
231. Oudejans JJ, Kummer JA, Jiwa M, et al. Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 1996;148:233-40. (Pubitemid 26022452)
232. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-1505. (Pubitemid 26354704)
233. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997;337:459-65. (Pubitemid 27333047)
234. Braeuninger A, Kuppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997;94:9337-42. (Pubitemid 27357830)
235. Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Eng J Med 1997;337:453-8. (Pubitemid 27333046)
236. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997;151:1123-30. (Pubitemid 27424322)
237. Arber DA, Weiss LM. CD15: a review. Appl Immunohistochem 1993;1:17-30.
238. Sheibani K, Battifora H, Burke JS, et al. Leu-M1 antigen in human neoplasms. An immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227-36. (Pubitemid 16069388)
239. Wieczorek R, Burke JS, et al. Leu-M1 antigen expression in T-cell neoplasia. Am J Pathol 1985;121:374-80. (Pubitemid 16183357)
240. Zutter MM, Hess JL. Guidelines for the diagnosis of leukemia or lymphoma in children. Am J Clin Pathol 1998;109:S9-22.
241. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995;85:1-14.
242. Schwarting R, Gerdes J, Durkop H, et al. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989;74:1678-89. (Pubitemid 19251546)
243. Durkop H, Foss HD, Eitelbach F, et al. Expression of the CD30 antigen in non-lymphoid tissues and cells. J Pathol 2000;190:613-8. (Pubitemid 30164492)
244. Miettinen M. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas. Arch Pathol Lab Med 1992;116:1197-1201.
245. Piris M, Brown DC, Gatter KC, et al. CD30 expression in non-Hodgkin's lymphoma. Histopathology 1990;17:211-8. (Pubitemid 20275962)
246. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996;88:645-56. (Pubitemid 26240396)
247. Piris M, Gatter KC, Mason DY. CD30 expression in follicular lymphoma. Histopathology 1991;18:25-9.
248. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol 1997;150:543-62. (Pubitemid 27073784)
249. Padmore RF, Finn WG, Singleton TP, et al. Fascn expression in immnophenotypic variants of classical Hodgkin's disease. Mod Pathol 1999;12:144A.
250. Perez-Ordonez B, Erlandson RA, Rosai J. Follicular dendritic cell tumor: report of 13 additional cases of a distinctive entity. Am J Surg Pathol 1996;20:944-55. (Pubitemid 26250634)
251. Isaacson PG. Malignant lymphomas with a follicular growth pattern. Histopathology 1996;28:487-95. (Pubitemid 26192945)
252. Baur AS, Meuge-Moraw C, Michel G, et al. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998;32:512-20. (Pubitemid 28277551)
253. Ashton-Key M, Thorpe PA, Allen JP, et al. Follicular Hodgkin's disease. Am J Surg Pathol 1995;19:1294-9.
254. Nakamura S, Nagahama M, Kagami Y, et al. Hodgkin's disease expressing follicular dendritic cell marker CD21 without any other B-cell marker: a clinicopathologic study of nine cases. Am J Surg Pathol 1999;23:363-76. (Pubitemid 29159997)
255. Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994;18:486-94. (Pubitemid 24134090)
256. Stevenson AJ, Chatten J, Bertoni F, et al. CD99 (p30/32MIC2) neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumors and the literature experience. Appl Immunohistochem 1994;2:231-40.
257. Dorfman DM, Kraus M, Perez-Atayde AR, et al. CD99 (p30/32MIC2) immunoreactivity in the diagnosis of leukemia cutis. Mod Pathol 1997;10:283-8. (Pubitemid 27228874)
258. Riopel M, Dickman PS, Link MP, et al. MIC2 analysis in pediatric lymphomas and leukemias. Hum Pathol 1994;25:396-9. (Pubitemid 24151126)
259. Robertson PB, Neiman RS, Worapongpaiboon S, et al. 013 (CD99) positivity in hematologic proliferations correlates with TdT positivity. Mod Pathol 1997;10:277-82. (Pubitemid 27228873)
260. Soslow RA, Bhargava V, Warnke RA. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol 1997;28:1158-65. (Pubitemid 27446602)
261. Vartanian RK, Sudilovsky D, Weidner N. Immunostaining of monoclonal antibody O13 [anti-MIC2 gene product (CD99)] in lymphomas: impact of heat-induced epitope retrieval. Appl Immunohistochem 1996;4:43-55.
262. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61. (Pubitemid 12201326)
263. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 1996;10:1081-1109.
264. Purtilo DT. Malignant lymphoma in children with primary immunodeiciency disease. Clin Transplant 1992;6:223-6.
265. Baumforth KR, Young LS, Flavell KJ, et al. The Epstein-Barr virus and its association with human cancers. Mol Pathol 1999;52:307-22. (Pubitemid 30002763)
266. Hummel M, Anagnastopoulos I, Korbjuhn P, et al. Epstein-Barr virus infection patterns in malignant lymphoma. The Epstein-Barr Virus and associated diseases. Tursz T, Pagano JS, Ablashi DV, et al., eds. Berlin: John Libbey Eurotext, Ltd., 193:433-41.
267. Gulley ML, Raab-Traub N. Detection of Epstein-Barr virus in human tissues by molecular genetic techniques. Arch Pathol & Lab Med 1993;117:1115-20. (Pubitemid 23339154)
268. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996;87:706-11. (Pubitemid 26030326)
269. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338:1413-21. (Pubitemid 28221982)
270. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375-85. (Pubitemid 30127473)
271. Said JW. Human immunodeficiency virus-related lymphoid proliferations. Semin Diagn Pathol 1997;14:48-53. (Pubitemid 27078885)
272. Weinreb M, Day PJ, Niggli F, et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child 1996;74:27-31. (Pubitemid 26039949)
273. Jarrett RF, Gallagher A, Jones DB, et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J Clin Pathol 1991;44:844-8.
274. Chang KL, Albujar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993;81:496-501. (Pubitemid 23027170)
275. Weinreb M, Day PJ, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996;87:3828-36. (Pubitemid 26129611)
276. d'Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood 1996;87:1045-55. (Pubitemid 26049875)
277. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
278. Duchrow M, Schluter C, Wohlenberg C, et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 1996;29:1-12. (Pubitemid 26086057)
279. Duchrow M, Gerdes J, Schluter C. The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif 1994;27:235-42. (Pubitemid 24148606)
280. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22. (Pubitemid 30054364)
281. Key G, Becker MH, Baron B, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68:629-36. (Pubitemid 23202791)
282. Miller TP, Grogan TM, Dahlberg Set al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994;83:1460-6. (Pubitemid 24081556)
283. Piris MA, Villuendas R, Martinez JC, et al. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995;17:35-42.
284. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004. (Pubitemid 23293979)
285. Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993;82:2289-95. (Pubitemid 23304250)
286. Adamson DJ, Thompson WD, Dawson AA, et al. p53 mutation and expression in lymphoma. Br J Cancer 1995;72:150-4.
287. Villuendas R, Piris MA, Algara P, et al. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993;82:3151-6. (Pubitemid 23334944)
288. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996;87:4302-10. (Pubitemid 26152272)
289. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996;87:3351-9. (Pubitemid 26115366)
290. Zoldan MC, Inghirami G, Masuda Y, et al. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol 1996;93:475-86. (Pubitemid 26148752)
291. Navaratnam S, Williams GJ, Rubinger M, et al. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. Leuk Lymphoma 1998;29:139-44. (Pubitemid 28236547)
292. Danks MK, Whipple DO, McPake CR, et al. Differences in epitope accessibility of p53 monoclonal antibodies suggest at least three conformations or states of protein binding of p53 protein in human tumor cell lines. Cell Death Differ 1998;5:678-86. (Pubitemid 28391370)
293. Horne GM, Anderson JJ, Tiniakos Dget al. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 1996;73:29-35. (Pubitemid 26026256)
294. Imam SA, Young L, Chaiwun B, et al. Comparison of two microwave based antigen-retrieval solutions in unmasking epitopes in formalin-fixed tissue for immunostaining. Anticancer Res 1995;15:1153-8.
295. Shin HJ, Kalapurakal SK, Lee JJ, et al. Comparison of p53 immunoreactivity in fresh-cut versus stored slides with and without microwave heating. Mod Pathol 1997;10:224-30. (Pubitemid 27130460)
296. Orazi A, Cattoretti G, John K, et al. Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections. Mod Pathol 1994;7:582-6.
297. Quintanilla-Martinez L, Zukerberg LR, Ferry JA, et al. Extramedullary tumors of lymphoid or myeloid blasts. The role of immunohistology in diagnosis and classification. Am J Clin Pathol 1995;104:431-43.
298. Suzumiya J, Ohshima K, Kikuchi M, et al. Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections: a useful method for the diagnosis of lymphoblastic lymphoma. J Pathol 1997;182:86-91. (Pubitemid 27240453)
299. Orazi A, Cotton J, Cattoretti G, et al. Terminal deoxynucleotidyl transferase staining in acute leukemia and normal bone marrow in routinely processed paraffin sections. Am J Clin Pathol 1994;102:640-5. (Pubitemid 24337558)
300. Braziel RM, Keneklis T, Donlon JA, et al. Terminal deoxynucleotidyl transferase in non-Hodgkin's lymphoma. Am J Clin Pathol 1983;80:655-9. (Pubitemid 14228993)
301. Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. Leukemia 1993;7:1142-50. (Pubitemid 23256460)
302. NCCLS. Quality assurance for immunocytochemistry; approved guideline. National Committee for Clinical Laboratory Standards document MM4A 1999;19[26]:1-68.
303. Swanson PE. Labels, disclaimers, and rules (oh, my!). Analyte-specific reagents and practice of immunohistochemistry. Am J Clin Pathol 1999;111:445-8. (Pubitemid 29153140)
304. Taylor CR. FDA issues final rule for classification and reclassification of immunochemistry reagents and kits. Am J Clin Pathol 1999;111:443-4.